Cidel Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$483K Buy
775
+56
+8% +$38.1K 0.02% 269
2026
Q1
$556K Buy
719
+130
+22% +$99.5K 0.03% 218
2025
Q4
$455K Buy
589
+21
+4% +$14.3K 0.03% 216
2025
Q3
$319K Buy
568
+107
+23% +$60.5K 0.02% 264
2025
Q2
$242K Buy
461
+78
+20% +$43.5K 0.01% 312
2025
Q1
$243K Buy
383
+52
+16% +$35.8K 0.02% 288
2024
Q4
$236K Buy
331
+34
+11% +$28.5K 0.02% 292
2024
Q3
$312K Hold
297
0.02% 252
2024
Q2
$312K Hold
297
0.02% 239
2024
Q1
$286K Hold
297
0.02% 259
2023
Q4
$261K Buy
+297
New +$245K 0.01% 262

Other funds holding REGN

Cidel Asset Management's REGN Position: Q2 2026 in Review

Cidel Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 7.8% in Q2 2026, buying an estimated $38.1K and bringing the position to 775 shares worth $483K. The position accounts for 0.02% of the portfolio, ranked #269.

Cidel Asset Management first reported a position in REGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $556K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Cidel Asset Management held 775 shares of Regeneron Pharmaceuticals worth $483K as of Q2 2026.
  • Cidel Asset Management bought 56 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $38.1K.
  • Regeneron Pharmaceuticals made up 0.02% of Cidel Asset Management's portfolio in Q2 2026, its #269 holding.
  • Cidel Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Cidel Asset Management's Regeneron Pharmaceuticals position peaked at $556K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Cidel Asset Management's 13F filing for Q2 2026, filed 17 Jul 2026.